Gilead Sciences (GILD) PT Lowered to $108 at Piper Jaffray

Jefferies Remains Sidelined on Gilead Sciences (GILD) Following 2Q - PT to $93

Jefferies maintained a Hold rating on Gilead Sciences (NASDAQ: GILD), and cut the price target to $93.00 (from $97.00) following the company's 2Q earnings report. GILD's strong bottom-line results were driven by HIVB strength, as well as buybacks. HIV sales remain strong, with particular... More

Gilead Sciences (GILD) PT Bumped to $98 at BMO Capital Posts Q2, Remains Sidelined

BMO Capital analyst Ian Somaiya bumped his price target on Gilead Sciences (NASDAQ: GILD) to $98.00 (from $97.00) but maintained a Market Perform rating following Q2 results after the close.

Somaiya commented, "Gilead's 2Q16 results support our below-consensus view of the company's HCV... More

Gilead Sciences (GILD) PT Trimmed to $115 at Credit Suisse

Credit Suisse analyst Alethia Young lowered estimates and her price target on Gilead Sciences (NASDAQ: GILD) to $115.00 (from $120.00) following results but maintained a Outperform rating.

Young commented, "Harvoni was the focus heading into the quarter; it missed consensus and guidance was lowered (likely due to HCV). Total revenues... More

Needham & Company Downgrades Gilead Sciences (GILD) to Hold

Needham & Company downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Hold.

Analyst Alan Carr commented, "Gilead reported 2Q16 financial results yesterday. Product sales of $7.65B were consistent w/ our $7.71B and consensus $7.77B expectations. WW Harvoni and Sovaldi sales were $2.56B and $1.36B... More

Gilead Sciences (GILD): Lower Revenue Guidance Highlights Concerns - Baird

Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) but is incrementally more cautious after earnings. Though Hep C sales met expectations, management didn't show as much confidence in a stabilization as they have in the... More

Gilead Sciences (GILD) Tops Q2 EPS by 6c

Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $3.08, $0.06 better than the analyst estimate of $3.02. Revenue for the quarter came in at $7.78 billion versus the consensus estimate of $7.79 billion.

otal product sales for the second quarter of 2016 were $7.7 billion compared to $8.1 billion for the same period in 2015. Product sales for the second quarter of 2016 were $4.9... More